New Treatment Options for MASLD Patients with Type 2 Diabetes - PubMed
5 hours ago
- #Liver Fibrosis
- #Type 2 Diabetes
- #MASLD
- MASLD is linked to type 2 diabetes (T2DM) and includes conditions like liver steatosis, fibrosis, cirrhosis, and hepatocellular carcinoma.
- Patients with MASLD have a higher risk of developing T2DM compared to the general population.
- International guidelines recommend using the FIB-4 index and transient elastography to identify high-risk patients for fibrotic progression.
- GLP-1RAs and SGLT2is are effective in improving hepatic steatosis and fibrosis in MASLD patients with T2DM.
- GLP-1RAs improve insulin signaling, lipid metabolism, reduce inflammation, and decrease oxidative stress in hepatocytes.
- European guidelines recommend resmetirom for non-cirrhotic MASH with significant fibrosis and GLP-1RAs for MASH, including compensated cirrhosis.
- The review highlights the complex relationship between MASLD and T2DM and the effects of glucose-lowering therapies on liver health.